People with diabetes, particularly severe diabetes, tend to lose less weight with GLP-1s than people without diabetes, so microdosing is less likely to be as effective, though their dose should only be increased as they tolerate it. George said that in her professional opinion, microdosing is a potential option for patients with smaller amounts of weight to lose or as a bridge to start, or wean off, regular GLP-1 medications
Most side effects are gastrointestinal in nature and tend to be most noticeable during the dose escalation phase
Compounded formulations of GLP-1s are not reviewed by the FDA for safety, efficacy, or quality
We dont assume the medication will only have positive effects
[12] [13] As a precautionary measure, people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2 (MEN2) should discuss this with their clinical team before enrolment in any trial involving this drug class
The first week typically marks the beginning of these changes, with the full effect becoming more pronounced in the following weeks